Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care

Clinical and Translational Allergy

Mike Thomas⁴  Alison Chisholm³  Clifford Godley⁵  Anne Copland²  Kevin Gruffydd-Jones¹  Daryl Freeman⁷  Shuna Gould⁶  Julie Von Ziegenweidt⁶  Annie Burden⁶  Dermot Ryan⁸  David Price⁹ 

[1] Box Surgery, Wiltshire; Respiratory Lead, Royal College of General Practitioners, London, and Honorary Lecturer, University of Bath, Bath, UK;Woodstock Medical Centre, Lanark, UK;Respiratory Effectiveness Group, Cambridge, UK;Primary Care Research, University of Southampton, Southampton, UK;Avondale Medical Practice, Strathaven, UK;Research in Real Life, Cambridge, UK;Mundesley Medical Practice and Norfolk Community Health & Care, Norfolk, UK;Woodbrook Medical Centre, Loughborough and Honorary Fellow at the University of Edinburgh, Edinburgh, UK;Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK

关键词: Steroid-responsive disease;    On-going asthma management;    Diagnosis;    Practical guidance;    Fractional exhaled nitric oxide (FeNO);   

Others  :  794145
DOI  :  10.1186/2045-7022-3-37

 received in 2013-07-19, accepted in 2013-10-18,  发布年份 2013

【 摘 要 】

Background

Fractional exhaled nitric oxide (FeNO) is a surrogate marker of eosinophilic airway inflammation and good predictor of corticosteroid response.

Aim

To evaluate how FeNO is being used to guide primary care asthma management in the United Kingdom (UK) with a view to devising practical algorithms for the use of FeNO in the diagnosis of steroid-responsive disease and to guide on-going asthma management.

Methods

Eligible patients (n = 678) were those in the Optimum Patient Care Research Database (OPCRD) aged 4–80 years who, at an index date, had their first FeNO assessment via NIOX MINO® or Flex®. Eligible practices were those using FeNO measurement in at least ten patients during the study period. Patients were characterized over a one-year baseline period immediately before the index date. Outcomes were evaluated in the year immediately following index date for two patient cohorts: (i) those in whom FeNO measurement was being used to identify steroid-responsive disease and (ii) those in whom FeNO monitoring was being used to guide on-going asthma management. Outcomes for cohort (i) were incidence of new ICS initiation at, or within the one-month following, their first FeNO measurement, and ICS dose during the outcome year. Outcomes for cohort (ii) were adherence, change in adherence (from baseline) and ICS dose.

Outcomes

In cohort (i) (n = 304) the higher the FeNO category, the higher the percentage of patients that initiated ICS at, or in the one month immediately following, their first FeNO measurement: 82%, 46% and 26% of patients with high, intermediate and low FeNO, respectively. In cohort (ii) (n = 374) high FeNO levels were associated with poorer baseline adherence (p = 0.005) but greater improvement in adherence in the outcome year (p = 0.017). Across both cohorts, patients with high FeNO levels were associated with significantly higher ICS dosing (p < 0.001).

Conclusions

In the UK, FeNO is being used in primary practice to guide ICS initiation and dosing decisions and to identify poor ICS adherence. Simple algorithms to guide clinicians in the practical use of FeNO could improved diagnostic accuracy and better tailored asthma regimens.

【 授权许可】

   
2013 Price et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Zacharasiewicz A, Wilson N, Lex C, Erin EM, Li AM, Hansel T, Khan M, Bush A: Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med 2005, 171:1077-1082.
• [2]NHLBI/WHO Workshop Report: Global strategy for asthma management and prevention. Bethesda, MD: National Institutes of Health. National Heart, Lung, and Blood Institute; 1995. Publication No. 95–3659
• [3]Global Initiative for Asthma: Global strategy for asthma management and prevention. 2012. http://www.ginasthma.org webcite
• [4]Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, Wardlaw AJ, Green RH: Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008, 178:218-224.
• [5]Bateman ED, Boushey HA, Bousquet J: Can guideline-defined asthma control Be achieved? the gaining optimal asthma controL study. Am J Respir Crit Care Med 2004, 170:36-844.
• [6]Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC: Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005, 172:831-836.
• [7]Grönke L, Kanniess F, Holz O, Jörres RA, Magnussen H: The relationship between airway hyper-responsiveness, markers of inflammation and lung function depends on the duration of the asthmatic disease. Clin Exp Allergy 2002, 32:57-63.
• [8]Langley SJ, Goldthorpe S, Custovic A, Woodcock A: Relationship among pulmonary function, bronchial reactivity, and exhaled nitric oxide in a large group of asthmatic patients. Ann Allergy Asthma Immunol 2003, 91:398-404.
• [9]Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID: Sputum eosinophilia and short-term response to Prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000, 356:1480-1485.
• [10]Brightling CE, Ward R, Wardlaw AJ, Pavord ID: Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis. Eur Respir J 2000, 15:682-686.
• [11]Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ: Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999, 353:2213-2214.
• [12]Green RH, Brightling CE, Woltmann G, Parker G, Wardlaw AJ, Pavord ID: Analysis of induced sputum in adults with asthma: identification of a sub group with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002, 57:875-879.
• [13]Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L, Dolovich J, Hargreave FE: Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998, 158(5 Pt 1):1511.
• [14]Berry M, Morgan A, Shaw DE, Parker D, Green R, Brightling C, Bradding P, Wardlaw AJ, Pavord ID: Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007, 62:43-49.
• [15]Rosi E, Ronchi MC, Grazzini M, Duranti R, Scano G: Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J Allergy Clin Immunol 1993, 3(2 Pt 1):232-237.
• [16]Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID: Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360:973-984.
• [17]Pearce N, Pekkanen J, Beasley R: How much asthma is really attributable to atopy? Thorax 1999, 54:268-272.
• [18]Douwes J, Gibson Pekkanen P, Pearce N: Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002, 57:643-648.
• [19]McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, Fahy JV: Asthma clinical research network of the national heart, lung, and blood institute.: a large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012, 185:612-619.
• [20]Frank TL, Adisesh A, Pickering AC, Morrison JF, Wright T, Francis H, Fletcher A, Frank PI, Hannaford P: Relationship between exhaled nitric oxide and childhood asthma. Am J Respir Crit Care Med 1998, 158:1032-1036.
• [21]Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, Pavord ID: The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005, 35:1175-1179.
• [22]Piacentini GL, Bodini A, Costella S, Vicentini L, Mazzi P, Sperandio S, Boner AL: Exhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic children. Eur Respir J 1999, 6:1386-1390.
• [23]Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A: Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral Prednisolone. Am J Respir Crit Care Med 2001, 64:1376-1381.
• [24]Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR: American thoracic society committee on interpretation of exhaled nitric oxide levels (FENO) for clinical applications: an official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical application. Am J Respir Crit Care Med 2011, 184:602-615.
• [25]Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G, Peter Herbison G, Robin Taylor D: Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005, 172:453-459.
• [26]Smith AD, Cowan JO, Filsell S, McLachlan C, Monti-Sheehan G, Jackson P, Taylor DR: Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004, 169:473.
• [27]Optimum patient care http://www.optimumpatientcare.org webcite
• [28]Petsky HL, Cates CJ, Li A, Lynaston JA, Turner C, Chang AB: Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev 2009., 2CD006340
• [29]Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, Chang AB: A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012, 67:199-208.
• [30]Fuhlbrigge A, Peden D, Apter AJ, Boushey HA, Camargo CA Jr, Gern J, Heymann PW, Martinez FD, Mauger D, Teague WG, Blaisdell C: Asthma outcomes: exacerbations. J Allergy Clin Immunol 2012, 129:S34e48.
• [31]Powell H, Murphy VE, Taylor DR, Hensley MJ, McCaffery K, Giles W, Clifton VL, Gibson PG: Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomized controlled trial. Lancet 2011, 378:983e90.
• [32]Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR: Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005, 352:2163e73.
• [33]Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, Pavord ID: The use of exhaled nitric oxide to guide asthma management. Am J Respir Crit Care Med 2007, 176:231e7.
• [34]Donohue JF, Jain N: Exhaled nitric oxide to predict corticosteroid responsiveness and reduced asthma exacerbation rates. Respir Med 2013, 107:943-952.
• [35]Mahr TA, Malka J, Spahn JD: Inflammometry in pediatric asthma: a review of factional exhaled nitric oxide in clinical practice. Allergy Asthma Proc 2013, 34:1-10.
• [36]Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID: Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002, 360:1715-1721.
• [37]Zeiger RS, Schatz M, Zhang F, Crawford WW, Kaplan MS, Roth RM, Chen W: Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids. J Allergy Clin Immunol 2011, 128:412-414.
• [38]Gelb AF, Taylor CF, Shinar CM, Gutierrez C, Zamel N: Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest 2006, 129:1492-1499.
• [39]Beck-Ripp JM, Griese S, Arenz C, Koring B, Pasqualoni B, Bufler P: Changes of exhaled nitric oxide during steroid treatment of childhood asthma. Eur Respir J 2002, 19:1015-1019.
• [40]Delgado-Corcoran C, Kissoon N, Murphy SP, Duckworth LJ: Exhaled nitric oxide reflects asthma severity and asthma control. Pediatr Crit Care Med 2004, 5:48-52.
• [41]Koster ES, Raaijmakers JA, Vijverberg SJ, Der Zee AH M-v: Inhaled corticosteroid adherence in paediatric patients: the PACMAN cohort study. Pharmacoepidemiol Drug Saf 2011, 20:1064-10772.
• [42]Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH: Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000, 117:542-550.
• [43]Persson MG, Zetterstrom O, Agrenius V, Ihre E, Gustafsson LE: Singlebreath nitric oxide measurements in asthmatic patients and smokers. Lancet 1994, 343:146-147.
• [44]Robbins RA, Millatmal T, Lassi K, Rennard S, Daughton D: Smoking cessation is associated with an increase in exhaled nitric oxide. Chest 1997, 112:313-318.
• [45]Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ: Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med 1995, 152:609-612.
• [46]Schilling J, Holzer P, Guggenbach M, Gyurech D, Marathia K, Geroulanos S: Reduced endogenous nitric oxide in the exhaled air of smokers and hypertensives. Eur Respir J 1994, 7:467-471.
• [47]Horvath I, Donnelly LE, Kiss A, Balint B, Kharitonov SA, Barnes PJ: Exhaled nitric oxide and hydrogen peroxide concentrations in asthmatic smokers. Respiration (Herrlisheim) 2004, 71:463-468.
• [48]American Thoracic Society / European Respiratory Society: ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005, 171:912-930.
• [49]Yavuz ST, Civelek E, Sahiner UM, Buyuktiryaki AB, Tuncer A, Karabulut E, Sekerel BE: Identifying uncontrolled asthma in children with the childhood asthma control test or exhaled nitric oxide measurement. Ann Allergy Asthma Immunol 2012, 109:36-40.
• [50]Green RJ, Klein M, Becker P, Halkas A, Lewis H, Kitchin O, Moodley T, Masekela R: Disagreement between common measures of asthma control in children. Chest 2013, 143:117-122.
• [51]Stern G, De Jongste J, van der Valk R, Baraldi E, Carraro S, Thamrin C, Frey U: Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children. J Allergy Clin Immunol 2011, 128:293-300.
• [52]Lester D, Mohammad A, Hernandez PI, Leach EE, Walker EA: An investigation of asthma care best practices in a community health center. J Health Care Poor Underserv 2012, 23(3 Suppl):255-264.
• [53]Wang L, Hollenbeak CS, Mauger DT, Zeiger RS, Paul IM, Sorkness CA, Lemanske RF Jr, Martinez FD, Strunk RC, Szefler SJ, Taussig LM: Childhood asthma research and education network of the national heart, lung, and blood institute: cost-effectiveness of fluticasone versus Montelukast in children with mild-to-intermediate persistent asthma in the pediatric asthma controller trial. J Allergy Clin Immunol 2011, 127:161-166.
• [54]Price D, Berg J, Lindgren P: An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. Allergy 2009, 64:431-438.
• [55]Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, Cherniack RM, Chinchilli VM, Craig T, Denlinger L, DiMango EA, Engle LL, Fahy JV, Grant JA, Israel E, Jarjour N, Kazani SD, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF, Lugogo N, Martin RJ, Meyers DA, Moore WC, Pascual R, Peters SP, Ramsdell J, Sorkness CA, Sutherland ER, et al.: Asthma clinical research network of the national heart, lung, and blood institute: comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA 2012, 308:987-997.